drugset / Trial / NCT00572806

Initiation of Insulin Aspart in Type 2 Diabetes

NCT00572806

Phase 4 Completed 6 enrolled Novo Nordisk A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate if using insulin aspart as start therapy will improve the efficacy on daytime blood glucose cycle profile in subjects with type 2 diabetes.

Timeline

Start
2003-02-05
Primary completion
2004-02-02
Completion
2004-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic